BioVentrix ~ $7,040,000 Series B Preferred Stock ~ May 2006
BioVentrix is a privately held medical device company that manufactures and develops solutions for the surgical treatment of congestive heart failure, a disease that affects over 5 million people in the US alone. Its first product, the Blue Egg, is used for the surgical restoration of the left ventricle.
The Company is transitioning a successful open surgical technique into a minimally invasive cardiac catheterization procedure. Through a Series B financing, Taglich Brothers provided BioVentrix capital it sought for growth in addition to help develop and commercialize the next generation of minimally invasive ventricular restoration techniques.
The information contained herein does not constitute a solicitation of any order to buy or sell any securities. The information provided herein may be displayed and printed for your personal, noncommercial use only. You may not reproduce, retransmit, distribute, disseminate, sell, publish, broadcast or circulate the information to anyone, without the express written consent of Taglich Brothers, Inc.